BIOASIS TECHNOLOGIES INC (BTI.CA) Fundamental Analysis & Valuation

TSX-V:BTI • CA09064N1033

Current stock price

0.005 CAD
0 (0%)
Last:

This BTI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BTI.CA Profitability Analysis

1.1 Basic Checks

  • BTI had negative earnings in the past year.
  • In the past year BTI has reported a negative cash flow from operations.
BTI.CA Yearly Net Income VS EBIT VS OCF VS FCFBTI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -2M -4M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -163.11%, BTI is in line with its industry, outperforming 41.67% of the companies in the same industry.
Industry RankSector Rank
ROA -163.11%
ROE N/A
ROIC N/A
ROA(3y)-180.01%
ROA(5y)-234.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTI.CA Yearly ROA, ROE, ROICBTI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTI.CA Yearly Profit, Operating, Gross MarginsBTI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K

0

2. BTI.CA Health Analysis

2.1 Basic Checks

  • BTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BTI has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for BTI is higher compared to a year ago.
BTI.CA Yearly Shares OutstandingBTI.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
BTI.CA Yearly Total Debt VS Total AssetsBTI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M

2.2 Solvency

  • BTI has an Altman-Z score of -41.85. This is a bad value and indicates that BTI is not financially healthy and even has some risk of bankruptcy.
  • BTI has a Altman-Z score of -41.85. This is in the lower half of the industry: BTI underperforms 70.83% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -41.85
ROIC/WACCN/A
WACC6.78%
BTI.CA Yearly LT Debt VS Equity VS FCFBTI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 1M -1M -2M -3M

2.3 Liquidity

  • BTI has a Current Ratio of 0.11. This is a bad value and indicates that BTI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of BTI (0.11) is worse than 87.50% of its industry peers.
  • BTI has a Quick Ratio of 0.11. This is a bad value and indicates that BTI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.11, BTI is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
BTI.CA Yearly Current Assets VS Current LiabilitesBTI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M

2

3. BTI.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.43% over the past year.
  • The Revenue has grown by 613.97% in the past year. This is a very strong growth!
  • Measured over the past years, BTI shows a very negative growth in Revenue. The Revenue has been decreasing by -40.66% on average per year.
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)613.97%
Revenue growth 3Y-70.17%
Revenue growth 5Y-40.66%
Sales Q2Q%294.75%

3.2 Future

  • Based on estimates for the next years, BTI will show a decrease in Earnings Per Share. The EPS will decrease by -5.27% on average per year.
  • Based on estimates for the next years, BTI will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y-16.67%
EPS Next 2Y-8.01%
EPS Next 3Y-5.27%
EPS Next 5YN/A
Revenue Next Year215.79%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BTI.CA Yearly Revenue VS EstimatesBTI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
BTI.CA Yearly EPS VS EstimatesBTI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 0 0.02 -0.02 -0.04 -0.06

0

4. BTI.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • BTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTI.CA Price Earnings VS Forward Price EarningsBTI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTI.CA Per share dataBTI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06

4.3 Compensation for Growth

  • BTI's earnings are expected to decrease with -5.27% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.01%
EPS Next 3Y-5.27%

0

5. BTI.CA Dividend Analysis

5.1 Amount

  • BTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BTI.CA Fundamentals: All Metrics, Ratios and Statistics

BIOASIS TECHNOLOGIES INC

TSX-V:BTI (3/18/2024, 7:00:00 PM)

0.005

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)01-26
Inst Owners0.08%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap397.07K
Revenue(TTM)269.38K
Net Income(TTM)-2.88M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.47
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -163.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-180.01%
ROA(5y)-234.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -41.85
F-Score3
WACC6.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-16.67%
EPS Next 2Y-8.01%
EPS Next 3Y-5.27%
EPS Next 5YN/A
Revenue 1Y (TTM)613.97%
Revenue growth 3Y-70.17%
Revenue growth 5Y-40.66%
Sales Q2Q%294.75%
Revenue Next Year215.79%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y14.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-719.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-719.99%
OCF growth 3YN/A
OCF growth 5YN/A

BIOASIS TECHNOLOGIES INC / BTI.CA Fundamental Analysis FAQ

What is the fundamental rating for BTI stock?

ChartMill assigns a fundamental rating of 0 / 10 to BTI.CA.


What is the valuation status for BTI stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOASIS TECHNOLOGIES INC (BTI.CA). This can be considered as Overvalued.


Can you provide the profitability details for BIOASIS TECHNOLOGIES INC?

BIOASIS TECHNOLOGIES INC (BTI.CA) has a profitability rating of 0 / 10.


What is the financial health of BIOASIS TECHNOLOGIES INC (BTI.CA) stock?

The financial health rating of BIOASIS TECHNOLOGIES INC (BTI.CA) is 0 / 10.